Barclays raised the firm’s price target on Encompass Health (EHC) to $129 from $118 and keeps an Overweight rating on the shares following the Q1 report. The firm continues to view Encompass as one of the most defensive stocks in its coverage that is largely insulated from current policy risk.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHC:
- Encompass Health: Strong Financial Performance and Resilient Growth Justify Buy Rating
- Encompass Health Appoints New COO Patrick W. Tuer
- Encompass Health names Patrick Tuer as COO, effective immediately
- Encompass Health reports Q1 adjusted EPS $1.37, consensus $1.19
- Encompass Health raises FY25 adjusted EPS view to $4.85-$5.10 from $4.67-$4.96